CA2126212A1 - Nouvelle molecule inhibant la fonction biologique du neuropeptide-tyrosine - Google Patents

Nouvelle molecule inhibant la fonction biologique du neuropeptide-tyrosine

Info

Publication number
CA2126212A1
CA2126212A1 CA002126212A CA2126212A CA2126212A1 CA 2126212 A1 CA2126212 A1 CA 2126212A1 CA 002126212 A CA002126212 A CA 002126212A CA 2126212 A CA2126212 A CA 2126212A CA 2126212 A1 CA2126212 A1 CA 2126212A1
Authority
CA
Canada
Prior art keywords
molecule
null
peptide
arg
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002126212A
Other languages
English (en)
Inventor
Albert Tseng
Adam S. Inglis
Lisa Selbie
Erica Potter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Prince of Wales Medical Research Institute Ltd POWMRI
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2126212A1 publication Critical patent/CA2126212A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
CA002126212A 1991-12-19 1992-12-21 Nouvelle molecule inhibant la fonction biologique du neuropeptide-tyrosine Abandoned CA2126212A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL010691 1991-12-19
AUPL0106 1991-12-19

Publications (1)

Publication Number Publication Date
CA2126212A1 true CA2126212A1 (fr) 1993-07-08

Family

ID=3775895

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002126212A Abandoned CA2126212A1 (fr) 1991-12-19 1992-12-21 Nouvelle molecule inhibant la fonction biologique du neuropeptide-tyrosine

Country Status (4)

Country Link
EP (1) EP0672054A4 (fr)
JP (1) JPH08501055A (fr)
CA (1) CA2126212A1 (fr)
WO (1) WO1993012139A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
DE69724941T2 (de) * 1996-03-21 2004-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyridin-derivate
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
WO2004098591A2 (fr) 2003-05-05 2004-11-18 Probiodrug Ag Inhibiteurs de glutaminyl-cyclase
EP1680120A2 (fr) 2003-11-03 2006-07-19 Probiodrug AG Combinaisons utiles au traitement de troubles neuronaux
CN1918131B (zh) 2004-02-05 2011-05-04 前体生物药物股份公司 谷氨酰胺酰基环化酶抑制剂
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EP2481408A3 (fr) 2007-03-01 2013-01-09 Probiodrug AG Nouvelle utilisation d'inhibiteurs glutaminyle cyclase
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH490338A (de) * 1967-04-13 1970-05-15 Ciba Geigy Verfahren zur Herstellung von ACTH-wirksamen Peptiden mit verlängerter Wirkung
GB8525852D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
DE3811193A1 (de) * 1988-04-01 1989-10-19 Boehringer Ingelheim Kg Neue peptide, verfahren zu ihrer herstellung und diese peptide enthaltende pharmazeutische zusammensetzungen
ZA896376B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y agonists
DE3939797A1 (de) * 1989-12-01 1991-06-06 Basf Ag Neue vom neuropeptid y abgeleitete peptide
DE59006842D1 (de) * 1990-03-30 1994-09-22 Heumann Pharma Gmbh & Co Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung.
SE467340B (sv) * 1990-07-04 1992-07-06 Perstorp Ab Anvaendning av inositolmonofosfat foer framstaellning av ett laekemedel effektivt som en neuropeptid y-(npy-)antagonist
US5571695A (en) * 1991-11-06 1996-11-05 Garvan Institute Of Medical Research Human neuropeptide Y-Y1 receptor

Also Published As

Publication number Publication date
JPH08501055A (ja) 1996-02-06
EP0672054A4 (fr) 1996-02-07
EP0672054A1 (fr) 1995-09-20
WO1993012139A1 (fr) 1993-06-24

Similar Documents

Publication Publication Date Title
CA2126212A1 (fr) Nouvelle molecule inhibant la fonction biologique du neuropeptide-tyrosine
US6174862B1 (en) Neurotrophic peptides of activity dependent neurotrophic factor
AU2005224027B2 (en) Y2/Y4 selective receptor agonists for therapeutic interventions
US8962817B2 (en) Vectors encoding a paralytic peptide
EP0861261A4 (fr) Sequences nucleotidiques et proteiques de genes delta de vertebres et procedes fondes sur ces dernieres
KR101855242B1 (ko) 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
JP2002530430A (ja) Ｃ型肝炎ウイルスｎｓ３プロテアーゼ阻害用の医薬組成物
EP0813545A4 (fr) Sequences nucleotidiques et proteiques du gene dentele chez les vertebres et procedes fondes sur ces sequences
CA2559838A1 (fr) Agonistes selectifs du recepteur y2 utilises dans des interventions therapeutiques
SK88893A3 (en) Novel amylin antagonist peptides and uses therefor
ZA200607492B (en) Y2/Y4 selective receptor agonists for therapeutic interventions
EP0467279A2 (fr) Polypeptides ayant une activité productrice de c-AMP
KR100629013B1 (ko) Ｉｇｆ-ⅰ 및 -ⅱ를 억제하는 ｇｈ-ｒｈ의 길항 유사체
AU2006236006A1 (en) Cyclised a-conotoxin peptides
US5858975A (en) Oxyntomodulin peptide having cardiotonic activity and insulin release-bromating activity
WO1997015593A1 (fr) Antagonistes de la neurotrophine
US5149779A (en) Humoral hypercalcemic factor antagonists
EP0341962B1 (fr) Antagonistes du facteur humoral hypercalcémique
JP2006342170A (ja) ウロテンシン−ｉｉアゴニスト及びアンタゴニスト
US5114843A (en) Humoral hypercalcemic factor antagonists
AU662032B2 (en) A novel molecule which inhibits neuropeptide tyrosine biological function
CA2202496C (fr) Peptides neurotrophiques du facteur neurotrophique dependant de l'activite
WO1991007982A1 (fr) Traitement du hsv
AU2005202153A1 (en) Urotensin-II agonists
JPH04352798A (ja) ポリペプチド

Legal Events

Date Code Title Description
FZDE Dead